Advanced Cell Tech (ACTCD) 8.0800 $ACTCD
Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources
Business Wire - Fri Sep 05, 8:17AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTCD), a leader in the field of regenerative medicine, announced today that the US Patent and Trademark Office (USPTO) has issued U.S. patent 8,822,218 covering methods of manufacturing dendritic cells using a highly scalable processing involving a readily renewable stem cell source as the starting materials. The derivation process covered by the patent provides a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform.
Distinguished Scientists Join Advanced Cell Technology's New Scientific Advisory Board
Business Wire - Tue Sep 02, 8:12AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTCD), a leader in the field of regenerative medicine, announced today the addition of five leading scientists to its new Scientific Advisory Board. The Board will be chaired by Robert Langer, ScD, David H. Koch Institute Professor at MIT and member of ACT's Board of Directors.
Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources
Business Wire - Fri Sep 05, 8:17AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTCD), a leader in the field of regenerative medicine, announced today that the US Patent and Trademark Office (USPTO) has issued U.S. patent 8,822,218 covering methods of manufacturing dendritic cells using a highly scalable processing involving a readily renewable stem cell source as the starting materials. The derivation process covered by the patent provides a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform.
Distinguished Scientists Join Advanced Cell Technology's New Scientific Advisory Board
Business Wire - Tue Sep 02, 8:12AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTCD), a leader in the field of regenerative medicine, announced today the addition of five leading scientists to its new Scientific Advisory Board. The Board will be chaired by Robert Langer, ScD, David H. Koch Institute Professor at MIT and member of ACT's Board of Directors.
